{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023727","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.924834+00:00","generated_at":"2026-05-17T13:00:56.554244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Cocrystal Pharma Q2 2025 net loss narrows to $2.1M; cash at $4.8M; CDI-988 Phase 1 data positive","bullets":["Q2 2025 net loss of $2.1M ($0.20/share) vs $5.3M ($0.53/share) in Q2 2024, primarily on lower R&D costs.","Cash and equivalents $4.8M as of June 30, 2025, down from $9.9M at Dec 31, 2024; working capital $4.9M.","Favorable CDI-988 Phase 1 safety/tolerability data for all doses including 1200 mg; Phase 1b norovirus challenge study planned in 2025.","CC-42344 Phase 2a challenge study extended due to low influenza infection rates; compound active against H5N1 avian strain.","R&D expenses $1.1M in Q2 2025 vs $4.3M in Q2 2024; G&A $1.0M vs $1.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023727","json":"https://secwatch.observer/filing/0001641172-25-023727.json","markdown":"https://secwatch.observer/filing/0001641172-25-023727.md","text":"https://secwatch.observer/filing/0001641172-25-023727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/0001641172-25-023727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:00:56.554244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}